Cellectis S.A. (CLLS)
After hours:
| Previous close | 2.0500 |
| Open | 2.2200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.1570 - 2.4300 |
| 52-week range | 0.9630 - 3.7740 |
| Volume | |
| Avg. volume | 67,106 |
| Market cap | 230.216M |
| Beta (5Y monthly) | 3.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3700 |
| Earnings date | 28 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireFDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transplantation (HSCT) or relapse afterFDA ODD and RPDD designations for UCART22 marks an important step towards developing allogeneic CAR T products that would be readily available for all patients NEW YORK, July 25, 2024 (GLOBE NE
ZacksRegenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ZacksDown -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
